The heterogeneity of obsessive-compulsive disorder and its implications for treatment

Obsessive-Compulsive Disorder: Second Edition

Volumn , Issue , 2003, Pages 76-79

  Bellodi, Laura ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34347346442     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470861657.ch2     Document Type: Chapter

References (16)

1. 1A autoreceptors in the action of the selective serotonin reuptake receptors. Eur. J. Pharmacol., 260: 251-255.
2. Artigas F., Perez V., Alvarez E. (1994) Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry, 248: 248-251.
3. Mundo E., Guglielmo E., Bellodi L. (1998) Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind placebo-controlled study. Int. Clin. Psychopharmacol., 13: 219-224.
4. Diaferia G., Mundo E., Bianchi Y., Ronchi P. (1994) Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description. J. Clin. Psychopharmacol., 14: 78-79.
5. Ackerman D.L., Greenland S., Bystritsky A., Morgenstern H., Katz R.J. (1994) Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J. Clin. Psychopharmacol., 14: 247-254.
6. Ravizza L., Barzega G., Bellino S., Bogetto F., Maina G. (1995) Predictors of drug treatment response in obsessive-compulsive disorder. J. Clin. Psychiatry, 56: 368-373.
7. McDougle C.J., Goodman W.K., Leckman J.F., Lee N.C., Heninger G.R., Price L.H. (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry, 51: 302-308.
8. Carrasco J.L., Hollander E., Schnefer F.R., Liebowitz M.R. (1992) Treatment outcome of obsessive-compulsive disorder with comorbid social phobia. J. Clin. Psychiatry, 53: 387-391.
9. Baer L., Jenike M.A., Black D.W., Treece C., Rosenfeld R., Greist J. (1992) Effect of axis II diagnoses on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder. Arch. Gen. Psychiatry, 49: 862-866.
10. Mundo E., Erzegovesi S., Bellodi L. (1995) Follow-up of obsessive-compulsive patients treated with proserotonergic agents. J. Clin. Psychopharmacol., 15: 288-289.
11. Cavedini P., Erzegovesi S., Ronchi P., Bellodi L. (1997) Predictive value of obsessive-compulsive personality disorder in antiobsessional treatment. Eur. Neuropsychopharmacol., 7: 45-49.
12. Black D.W., Monahan P., Gable J., Blum N., Clancy G., Baker P. (1998) Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. J. Clin. Psychiatry, 59: 420-425.
13. Mataix-Cols D., Rauch S.L., Manzo P.A., Jenike M.A., Baer L. (1999) Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am. J. Psychiatry, 156: 1409-1416.
14. Alarcon R.D., Libb J.W., Spitler D. (1993) A predictive study of obsessivecompulsive disorder response to clomipramine. J. Clin. Psychopharmacol., 13: 210-213.
15. Mundo E., Bareggi S., Pirola R., Bellodi L. (1999) Effect of intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable? Biol. Psychiatry, 45: 290-294.
16. Erzegovesi S., Cavallini M.C., Cavedini P., Diaferia G., Locatelli M., Bellodi L. Clinical predictors of drug response in obsessive-compulsive disorder. Submitted for publication.